SG11201806496SA - Antigen binding proteins that bind pd-l1 - Google Patents

Antigen binding proteins that bind pd-l1

Info

Publication number
SG11201806496SA
SG11201806496SA SG11201806496SA SG11201806496SA SG11201806496SA SG 11201806496S A SG11201806496S A SG 11201806496SA SG 11201806496S A SG11201806496S A SG 11201806496SA SG 11201806496S A SG11201806496S A SG 11201806496SA SG 11201806496S A SG11201806496S A SG 11201806496SA
Authority
SG
Singapore
Prior art keywords
international
bind
january
pct
rule
Prior art date
Application number
SG11201806496SA
Inventor
Heyue Zhou
Original Assignee
Heyue Zhou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heyue Zhou filed Critical Heyue Zhou
Publication of SG11201806496SA publication Critical patent/SG11201806496SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property , Organization MD 1111101110101011111 HO 11111 0111011100101111101110101111111011 III International Bureau 0.. .... .. (10) International Publication Number (43) International Publication Date ..... .....!;,' WO 2017/132562 Al 3 August 2017 (03.08.2017) WI P0 I P CT (51) International Patent Classification: C12P 21/08 (2006.01) A61K 39/00 (2006.01) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (21) International Application Number: PCT/US2017/015429 RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (22) International Filing Date: ZA, ZM, ZW. 27 January 2017 (27.01.2017) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (26) Publication Language: English TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (30) Priority Data: 62/288,912 29 January 2016 (29.01.2016) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventor; and SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (71) Applicant : ZHOU, Heyue [CN/US]; 15732 Potomac GW, KM, ML, MR, NE, SN, TD, TG). Ridge Road, San Diego, CA 92127 (US). Published: (74) Agents: HERRITT, Danielle, L. et al.; McCarter & Eng- lish, LLP, 265 Franklin Street, Boston, MA 02110 (US). with international search report (Art. 21(3)) (81) Designated States (unless otherwise indicated, for every before the expiration of the time limit for amending the claims and to be republished in the event of receipt of kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, — DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) = 1-1 N kr) N M 11 IN 11 © (54) Title: ANTIGEN BINDING PROTEINS THAT BIND PD-L1 el 0 (57) : There is disclosed anti-PD-L1 IgG class antibodies that have an improved ability to be manufactured at higher yields. More specifically, there is disclosed human antibodies that bind PD -L1, PD-L1 -binding fragments that can be manufactured at high- er yields.
SG11201806496SA 2016-01-29 2017-01-27 Antigen binding proteins that bind pd-l1 SG11201806496SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662288912P 2016-01-29 2016-01-29
PCT/US2017/015429 WO2017132562A1 (en) 2016-01-29 2017-01-27 Antigen binding proteins that bind pd-l1

Publications (1)

Publication Number Publication Date
SG11201806496SA true SG11201806496SA (en) 2018-08-30

Family

ID=59386438

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806496SA SG11201806496SA (en) 2016-01-29 2017-01-27 Antigen binding proteins that bind pd-l1

Country Status (16)

Country Link
US (4) US10118963B2 (en)
EP (1) EP3408400B1 (en)
JP (3) JP6883590B2 (en)
KR (1) KR20190026642A (en)
CN (2) CN116333124A (en)
AU (1) AU2017212717B2 (en)
BR (1) BR112018015480A2 (en)
CA (1) CA3013051A1 (en)
CL (1) CL2018002034A1 (en)
EA (1) EA037855B1 (en)
IL (1) IL260846B2 (en)
MX (2) MX2018009228A (en)
PH (1) PH12018501611A1 (en)
SG (1) SG11201806496SA (en)
TW (1) TWI760323B (en)
WO (1) WO2017132562A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102163408B1 (en) * 2012-05-31 2020-10-08 소렌토 쎄라퓨틱스, 인코포레이티드 Antigen binding proteins that bind pd-l1
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
AU2017212717B2 (en) 2016-01-29 2023-11-16 Yuhan Corporation Antigen binding proteins that bind PD-L1
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
MX2020009550A (en) * 2018-03-22 2020-11-11 Keires Ag Antagonistic pd-1, pd-l1 and lag-3 binding proteins.
CN110869390B (en) * 2018-04-09 2021-05-11 上海原能细胞医学技术有限公司 anti-PD-L1 antibodies and uses thereof
WO2019227490A1 (en) * 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
AU2019275737A1 (en) * 2018-06-01 2021-01-21 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and uses thereof for treating disease or condition
CA3110138A1 (en) * 2018-08-20 2020-02-27 1Globe Biomedical Co., Ltd. Novel cancer immunotherapy antibody compositions
US20220177561A1 (en) * 2018-12-11 2022-06-09 Sanford Burnham Prebys Medical Discovery Institute Models and Methods Useful for the Treatment of Serrated Colorectal Cancer
EP3955925A4 (en) 2019-04-18 2023-03-22 QLSF Biotherapeutics Inc. Humanized anti-pd-l1 antibodies
AU2020339478A1 (en) * 2019-08-29 2021-05-06 Remegen Co., Ltd. Anti PD-L1 antibody and use thereof
JP2023539369A (en) 2020-09-02 2023-09-13 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ Antibody-nanoparticle conjugates and methods of making and using the same
JP2023552694A (en) 2020-11-16 2023-12-19 イミューンオンシア セラピューティクス インコーポレイテッド Biomarkers and their uses for predicting therapeutic response to immuno-anticancer drugs
KR20220152172A (en) 2021-05-07 2022-11-15 주식회사 이뮨온시아 Bispecific antibody specifically binding to cd47 and pd-l1
CA3221925A1 (en) 2021-06-09 2022-12-15 Sorrento Therapeutics, Inc. Method of treating cancer by administration of an anti-pd-1 or anti-pd-l1 therapeutic agent via a lymphatic microneedle delivery device
WO2024064640A2 (en) * 2022-09-19 2024-03-28 Sonoma Biotherapeutics, Inc. Citrullinated antigen-specific chimeric antigen receptors for targeting regulatory t cells to treat hidradenitis suppurativa
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3051145B2 (en) 1990-08-28 2000-06-12 住友製薬株式会社 Novel polyethylene glycol derivative modified peptide
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (en) 1991-06-03 1992-12-10 Behringwerke Ag TETRAVALENT BISPECIFIC RECEPTORS, THEIR PRODUCTION AND USE
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
JP3951062B2 (en) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド Expression of antibody fragments with cysteine present at least as a free thiol in E. coli for the production of bifunctional F (ab ') 2 antibodies
JPH05244982A (en) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd Humanized b-b10
EP0651761B1 (en) 1992-07-13 2002-10-09 Bionebraska, Inc. Method for modification of recombinant polypeptides
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
ATE240394T1 (en) 1992-10-23 2003-05-15 Immunex Corp METHODS FOR PRODUCING SOLUBLE OLIGOMERIC PROTEINS
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6938003B2 (en) 2000-06-30 2005-08-30 Mahesh Harpale Method and apparatus for a credibility reporting system to augment an online exchange
EP2295450B1 (en) 2000-09-29 2015-01-28 Merck Sharp & Dohme Corp. Pegylated interleukin-10
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
KR20210097209A (en) 2007-06-01 2021-08-06 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 Vaccine for the prevention of breast cancer relapse
US8877688B2 (en) * 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
KR102163408B1 (en) 2012-05-31 2020-10-08 소렌토 쎄라퓨틱스, 인코포레이티드 Antigen binding proteins that bind pd-l1
KR101947702B1 (en) * 2012-10-04 2019-02-14 다나-파버 캔서 인스티튜트 인크. Human monoclonal anti-pd-l1 antibodies and methods of use
AR093984A1 (en) * 2012-12-21 2015-07-01 Merck Sharp & Dohme ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN
JP6563906B2 (en) * 2013-05-31 2019-08-21 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Antigen binding protein that binds to PD-1
AU2015240454B2 (en) 2014-04-04 2019-08-22 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
CN105238762A (en) * 2015-10-26 2016-01-13 无锡傲锐东源生物科技有限公司 Anti-PD-1 protein monoclonal antibody hybridomas cell, anti- PD-1 monoclonal antibody generated by same and application
AU2017212717B2 (en) * 2016-01-29 2023-11-16 Yuhan Corporation Antigen binding proteins that bind PD-L1

Also Published As

Publication number Publication date
EP3408400A1 (en) 2018-12-05
JP2022095910A (en) 2022-06-28
IL260846B (en) 2022-10-01
AU2017212717A1 (en) 2018-09-06
TW201736400A (en) 2017-10-16
PH12018501611A1 (en) 2019-04-08
MX2018009228A (en) 2019-07-08
EA201891709A1 (en) 2019-01-31
US10919964B2 (en) 2021-02-16
KR20190026642A (en) 2019-03-13
CL2018002034A1 (en) 2019-03-15
US11919952B2 (en) 2024-03-05
EP3408400A4 (en) 2019-11-27
IL260846B2 (en) 2023-02-01
JP7140867B2 (en) 2022-09-21
TWI760323B (en) 2022-04-11
WO2017132562A8 (en) 2017-09-08
US20170218066A1 (en) 2017-08-03
WO2017132562A1 (en) 2017-08-03
AU2017212717B2 (en) 2023-11-16
EP3408400B1 (en) 2024-06-26
CA3013051A1 (en) 2017-08-03
US10118963B2 (en) 2018-11-06
US20240190959A1 (en) 2024-06-13
JP2021102633A (en) 2021-07-15
JP6883590B2 (en) 2021-06-09
JP2019507183A (en) 2019-03-14
MX2022011659A (en) 2022-10-13
EA037855B1 (en) 2021-05-27
US20210147539A1 (en) 2021-05-20
US20190092861A1 (en) 2019-03-28
IL260846A (en) 2018-09-20
CN109715821A (en) 2019-05-03
EP3408400C0 (en) 2024-06-26
BR112018015480A2 (en) 2019-05-21
CN116333124A (en) 2023-06-27
CN109715821B (en) 2022-09-06

Similar Documents

Publication Publication Date Title
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201909949XA (en) Targeted immunotolerance
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201901126UA (en) Combination therapy for cancer
SG11201903674YA (en) Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201905699XA (en) Anti-icos agonist antibodies and uses thereof
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201804856VA (en) C-terminal lysine conjugated immunoglobulins
SG11201811290VA (en) Compositions and methods for the depletion of cd117+cells
SG11201807538PA (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201903835WA (en) Antibodies directed against programmed death- 1 (pd-1)
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same